Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2007-03-13
2007-03-13
O'Hara, Eileen B. (Department: 1646)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S143100, C424S141100, C424S192100, C514S002600, C514S012200, C530S350000, C530S388220, C536S023500, C536S023400
Reexamination Certificate
active
09972218
ABSTRACT:
Provided is a method of suppressing an immune response in a subject by administering an antagonist of a MU-1 hematopoietin receptor superfamily chain protein.
REFERENCES:
patent: 5011912 (1991-04-01), Hopp et al.
patent: 5098833 (1992-03-01), Lasky et al.
patent: 5116964 (1992-05-01), Capon et al.
patent: 5155027 (1992-10-01), Sledziewski et al.
patent: 5216131 (1993-06-01), Lasky et al.
patent: 5225538 (1993-07-01), Capon et al.
patent: 5428130 (1995-06-01), Capon et al.
patent: 5447851 (1995-09-01), Beutler et al.
patent: 5455165 (1995-10-01), Capon et al.
patent: 5514582 (1996-05-01), Capon et al.
patent: 5567584 (1996-10-01), Sledziewski et al.
patent: 5714147 (1998-02-01), Capon et al.
patent: 5750375 (1998-05-01), Sledziewski et al.
patent: 5840844 (1998-11-01), Lasky et al.
patent: 5843725 (1998-12-01), Sledziewski et al.
patent: 6018026 (2000-01-01), Sledziewski et al.
patent: 6057128 (2000-05-01), Donaldson et al.
patent: 6136310 (2000-10-01), Hanna et al.
patent: 6291212 (2001-09-01), Sledziewski et al.
patent: 6291646 (2001-09-01), Sledziewski et al.
patent: 6300099 (2001-10-01), Sledziewski et al.
patent: 6307024 (2001-10-01), Novak et al.
patent: 6323323 (2001-11-01), Sledziewski et al.
patent: 6406697 (2002-06-01), Capon et al.
patent: 6576744 (2003-06-01), Presnell et al.
patent: 2002/0090680 (2002-07-01), Hodge
patent: 2002/0128446 (2002-09-01), Novak et al.
patent: 2002/0137677 (2002-09-01), Sprecher et al.
patent: 0 812 913 (1997-12-01), None
patent: 1 088 831 (2001-04-01), None
patent: WO 97/20926 (1997-06-01), None
patent: WO 97/31946 (1997-09-01), None
patent: WO 97/33913 (1997-09-01), None
patent: WO 97/47741 (1997-12-01), None
patent: WO 97/47742 (1997-12-01), None
patent: WO 98/10638 (1998-03-01), None
patent: WO 98/11225 (1998-03-01), None
patent: WO 98/31811 (1998-07-01), None
patent: WO 99/47675 (1999-09-01), None
patent: WO 00/08152 (2000-02-01), None
patent: WO 00/17235 (2000-03-01), None
patent: WO 00/53761 (2000-09-01), None
patent: WO 01/46261 (2001-06-01), None
GenBank Database Accession No. M26062 (Jan. 6, 1995).
Parrish-Novak, et al. (2000). “Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function”Nature408: 57-63.
Yan, et al. (2000). “Two-Amino Acid Molecular Switch in an Epithelial Morphogen that Regulates Binding to Two Distinct Receptors”Science290: 523-527.
Ozaki, et al. (2000). “Cloning of a type I cytokine receptor most related to the IL-2 receptor β chain”Proc. Natl. Acad. Sci. USA97(21): 11439-11444.
EMBL Database Accession No. AC002303 (Jun. 26, 1997).
Bazan (1990). “Structural design and molecular evolution of a cytokine receptor superfamily”Proc. Natl. Acad. Sci. USA87:6934-6938.
Dusanter-Fourt, et al. (1994). “Trasduction du signal par les recepteurs de cytokines”Medecine/Sciences10: 825-835. English Abstract.
Hatakeyama, et al. (1989). “Interleukin-2 Receptor beta Chain Gene: Generation of Three Receptor Forms by Cloned Human alpha and beta Chain cDNA's”Science244: 551-556.
D'Andrea, et al. (1989). “Expression Cloning of the Murine Erythropoietin Receptor”Cell57: 277-285.
O'Dowd, et al. (1997). “Cloning and chromosomal mapping of four putative novel human G-protein-coupled receptor genes”Gene187(1): 75-81.
International Search Report for PCT/US 99/05854. Mailed on Aug. 17, 1999.
Biró, et al., “The Effect of WSEWS Pentapeptide and WSEWS-Specific Monoclonal Antibodies on Constitutive and IL-6 Induced Acute-Phase Protein Production by a Human Hepatoma Cell Line, HEPG-2”,Immunology Letters, 46:183-187 (1995).
Caput, et al., “Cloning and Characterization of a Specific Interleukin (IL)-13 Binding Protein Structurally Related to the IL-5 Receptor α Chain,”Journal of Biological Chemistry, 271(28):16921-16926 (1996).
Database EMBL, ID HS795114 Accession No. R52795, May 25, 1995.
Database EMBL, Accession No. AF279436, Jul. 18, 2000.
Database EMBL, Accession No. AB049137, Sep. 23, 2000.
Debinski, et al., “A Novel Chimeric Protein Composed of Interleukin 13 and Pseudomonas Exotoxin is Highly Cytotoxic to Human Carcinoma Cells Expressing Receptors for Interleukin 13 and Interleukin 4,”Journal of Biological Chemistry, 270(28):16775-16780 (1995).
Lai, et al., “STAT3 and STAT5B Are Targets of Two Different Signal Pathways Activated by Hematopoietin Receptors and Control Transcription via Separate Cytokine Response Elements,”Journal of Biological Chemistry270(40):23254-23257 (1995).
Page, et al., “An Antiproliferative Bioassay for Interleukin-4,”Journal of Immunological Methods, 189:129-135, (1996).
Vita, et al., “Characterization and Comparison of the Interleukin 13 Receptor with the Interleukin 4 Receptor on Several Cell Types,”Journal of Biological Chemistry, 270(8):3512-3517 (1995).
Zhang, et al., “Identification, Purification, and Characterization of a Soluble Interleukin (IL)-13-Binding Protein,”Journal of Biological Chemistry, 272(14):9474-9480 (1997).
Carter Laura
Collins Mary
Donaldson Debra D.
Lowe Lesile D.
Unger Michelle
Genetics Institute LLC
O'Hara Eileen B.
LandOfFree
Methods of treatment with antagonists of MU-1 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treatment with antagonists of MU-1, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treatment with antagonists of MU-1 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3803415